1131 related articles for article (PubMed ID: 27522627)
21. Stereotactic Ablative Radiotherapy (SABR) in inoperable oligometastatic disease from colorectal cancer: a safe and effective approach.
Comito T; Cozzi L; Clerici E; Campisi MC; Liardo RL; Navarria P; Ascolese A; Tozzi A; Iftode C; De Rose F; Villa E; Personeni N; Rimassa L; Santoro A; Fogliata A; Mancosu P; Tomatis S; Scorsetti M
BMC Cancer; 2014 Aug; 14():619. PubMed ID: 25163798
[TBL] [Abstract][Full Text] [Related]
22. Radiosurgery and fractionated stereotactic radiotherapy in oligometastatic/oligoprogressive non-small cell lung cancer patients: Results of a multi-institutional series of 198 patients treated with "curative" intent.
Buglione M; Jereczek-Fossa BA; Bonù ML; Franceschini D; Fodor A; Zanetti IB; Gerardi MA; Borghetti P; Tomasini D; Di Muzio NG; Oneta O; Scorsetti M; Franzese C; Romanelli P; Catalano G; Dell'Oca I; Beltramo G; Ivaldi GB; Laudati A; Magrini SM; Antognoni P;
Lung Cancer; 2020 Mar; 141():1-8. PubMed ID: 31926440
[TBL] [Abstract][Full Text] [Related]
23. Long-term Follow-up and Patterns of Recurrence of Patients With Oligometastatic NSCLC Treated With Pulmonary SBRT.
Hörner-Rieber J; Bernhardt D; Blanck O; Duma M; Eich HT; Gerum S; Gkika E; Hass P; Henkenberens C; Herold HU; Hildebrandt G; Imhoff D; Kahl H; Janssen S; Jurianz K; Krempien R; Lautenschläger SF; Lohaus F; Mueller AC; Petersen C; Sackerer I; Scafa D; Schrade E; Uhlmann L; Wittig A; Guckenberger M
Clin Lung Cancer; 2019 Nov; 20(6):e667-e677. PubMed ID: 31327644
[TBL] [Abstract][Full Text] [Related]
24. Predictive factors for local control in primary and metastatic lung tumours after four to five fraction stereotactic ablative body radiotherapy: a single institution's comprehensive experience.
Thibault I; Poon I; Yeung L; Erler D; Kim A; Keller B; Lochray F; Jain S; Soliman H; Cheung P
Clin Oncol (R Coll Radiol); 2014 Nov; 26(11):713-9. PubMed ID: 25085765
[TBL] [Abstract][Full Text] [Related]
25. Stereotactic Body Radiation Therapy (SBRT) Using CyberKnife in Oligometastatic Cancer Patients; Retrospective Evaluation, Single Institution Experience.
Alsuhaibani A; Elashwah A; Alkafi A; Constantinescus C; ALzorkany F
J Gastrointest Cancer; 2019 Dec; 50(4):879-887. PubMed ID: 30291546
[TBL] [Abstract][Full Text] [Related]
26. Consolidative stereotactic ablative radiotherapy (SABR) to intrapulmonary lesions is associated with prolonged progression-free survival and overall survival in oligometastatic NSCLC patients: A prospective phase 2 study.
Blake-Cerda M; Lozano-Ruíz F; Maldonado-Magos F; de la Mata-Moya D; Díaz-García D; Lara-Mejía L; Zatarain-Barrón ZL; Cuevas-Góngora MF; Barron-Barron F; Corona-Cruz JF; Cabrera-Miranda L; Arroyo-Hernández M; Gerson R; Arrieta O
Lung Cancer; 2021 Feb; 152():119-126. PubMed ID: 33385737
[TBL] [Abstract][Full Text] [Related]
27. Stereotactic Ablative Radiation Therapy for Pulmonary Metastases: Histology, Dose, and Indication Matter.
Helou J; Thibault I; Poon I; Chiang A; Jain S; Soliman H; Erler D; Yeung L; Cheung P
Int J Radiat Oncol Biol Phys; 2017 Jun; 98(2):419-427. PubMed ID: 28463162
[TBL] [Abstract][Full Text] [Related]
28. Curative-intent radiotherapy in patients with oligometastatic lesions from colorectal cancer: A single-center study.
He X; Zhang P; Li Z; Bi F; Xu F; Wang X; Shen Y; Li Q; Qiu M
Medicine (Baltimore); 2018 Oct; 97(40):e12601. PubMed ID: 30290630
[TBL] [Abstract][Full Text] [Related]
29. Treatment Outcomes of Stereotactic Ablative Body Radiotherapy on Extra-cranial Oligometastatic and Oligoprogressive Breast Cancer: Mature Results from a Single Institution Experience.
Armstrong S; Makris A; Belessiotis-Richards K; Abdul-Latif M; Ostler P; Shah N; Miles D; Tsang YM
Clin Oncol (R Coll Radiol); 2024 Jun; 36(6):362-369. PubMed ID: 38575431
[TBL] [Abstract][Full Text] [Related]
30. Stereotactic Ablative Radiation Therapy for Pulmonary Recurrence-Based Oligometastatic Non-Small Cell Lung Cancer: Survival and Prognostic Value of Regulatory T Cells.
Liu C; Sun B; Hu X; Zhang Y; Wang Q; Yue J; Yu J
Int J Radiat Oncol Biol Phys; 2019 Dec; 105(5):1055-1064. PubMed ID: 31437470
[TBL] [Abstract][Full Text] [Related]
31. The impact of local control on overall survival after stereotactic body radiotherapy for liver and lung metastases from colorectal cancer: a combined analysis of 388 patients with 500 metastases.
Klement RJ; Abbasi-Senger N; Adebahr S; Alheid H; Allgaeuer M; Becker G; Blanck O; Boda-Heggemann J; Brunner T; Duma M; Eble MJ; Ernst I; Gerum S; Habermehl D; Hass P; Henkenberens C; Hildebrandt G; Imhoff D; Kahl H; Klass ND; Krempien R; Lewitzki V; Lohaus F; Ostheimer C; Papachristofilou A; Petersen C; Rieber J; Schneider T; Schrade E; Semrau R; Wachter S; Wittig A; Guckenberger M; Andratschke N
BMC Cancer; 2019 Feb; 19(1):173. PubMed ID: 30808323
[TBL] [Abstract][Full Text] [Related]
32. Ablative dose stereotactic body radiation therapy for oligometastatic disease: a prospective single institution study.
Burkon P; Kazda T; Pospisil P; Slavik M; Kominek L; Selingerova I; Blakaj DM; Prochazka T; Vrzal M; Rehak Z; Slampa P
Neoplasma; 2019 Mar; 66(2):315-325. PubMed ID: 30509112
[TBL] [Abstract][Full Text] [Related]
33. Long term control stereotactic body radiotherapy (SBRT) for oligometastatic colorectal cancer: a single center study.
Gil-Raga M; Meri-Abad M; Safont Aguilera MJ; Hernández Machancoses A; Lobo M; Calabuig-Fariñas S; López Torrecilla J; Herreros Pomares A; Camps Herrero C
Chin Clin Oncol; 2020 Apr; 9(2):13. PubMed ID: 32192350
[TBL] [Abstract][Full Text] [Related]
34. Stereotactic ablative radiotherapy and systemic treatments for extracerebral oligometastases, oligorecurrence, oligopersistence and oligoprogression from lung cancer.
Kissel M; Martel-Lafay I; Lequesne J; Faivre JC; Le Péchoux C; Stefan D; Barraux V; Loiseau C; Grellard JM; Danhier S; Lerouge D; Chouaid C; Gervais R; Thariat J
BMC Cancer; 2019 Dec; 19(1):1237. PubMed ID: 31856742
[TBL] [Abstract][Full Text] [Related]
35. Lung metastases treated with stereotactic body radiotherapy: the RSSearch® patient Registry's experience.
Ricco A; Davis J; Rate W; Yang J; Perry D; Pablo J; D'Ambrosio D; Sharma S; Sundararaman S; Kolker J; Creach KM; Lanciano R
Radiat Oncol; 2017 Feb; 12(1):35. PubMed ID: 28143558
[TBL] [Abstract][Full Text] [Related]
36. Clinical outcomes of stereotactic brain and/or body radiotherapy for patients with oligometastatic lesions.
Inoue T; Katoh N; Aoyama H; Onimaru R; Taguchi H; Onodera S; Yamaguchi S; Shirato H
Jpn J Clin Oncol; 2010 Aug; 40(8):788-94. PubMed ID: 20406944
[TBL] [Abstract][Full Text] [Related]
37. Superior outcomes of nodal metastases compared to visceral sites in oligometastatic colorectal cancer treated with stereotactic ablative radiotherapy.
O'Cathail SM; Smith T; Owens R; Zeniou A; Tsang Y; Holyoake DLP; Murray L; Harrison M; Hawkins MA
Radiother Oncol; 2020 Oct; 151():280-286. PubMed ID: 32866563
[TBL] [Abstract][Full Text] [Related]
38. Short-term outcomes and clinical efficacy of stereotactic body radiation therapy (SBRT) in treatment of adrenal gland metastases from lung cancer.
Zhao X; Zhu X; Fei J; Ren H; Cao Y; Ju X; Yuan Z; Zhang H
Radiat Oncol; 2018 Oct; 13(1):205. PubMed ID: 30348187
[TBL] [Abstract][Full Text] [Related]
39. Stereotactic body radiotherapy for colorectal lung oligometastases: preliminary single-institution results.
Carvajal C; Navarro-Martin A; Cacicedo J; Ramos R; Guedea F
J BUON; 2015; 20(1):158-65. PubMed ID: 25778311
[TBL] [Abstract][Full Text] [Related]
40. Oligometastases from prostate cancer: local treatment with stereotactic body radiotherapy (SBRT).
Habl G; Straube C; Schiller K; Duma MN; Oechsner M; Kessel KA; Eiber M; Schwaiger M; Kübler H; Gschwend JE; Combs SE
BMC Cancer; 2017 May; 17(1):361. PubMed ID: 28532400
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
